A novel, first-in-class hypo recovery drink, designed to deliver complete recovery for your patients.
Most clinicians visiting this page already know Klario as a new option for self-managed hypoglycaemia recovery. This section summarises what is new and clinically relevant, so you can confidently advise patients on when Klario may be appropriate alongside existing guidance.
Real-world patient experiences from clinical trial participants, showing how measured clinical gains with Klario translate into everyday quality of life improvements that your patients care about most.
Standard glucose corrects blood sugar, but the brain often remains under-fuelled after a hypo. Utilisation of glucose by neurons may be limited by inhibition of glycolysis due to NAD+ depletion.
Klario combines 15 g of fast-acting carbohydrates with BHB and lactate - adaptive energy sources which cross the blood brain barrier to provide efficient energy delivery when glycolysis is compromised.
In the 12-week randomised study, Klario improved post-hypo time-in-range and reduced recurrent hypoglycaemia by 27% compared with standard glucose-only products.
Statistically significant improvements in speed of symptom relief, resolution of after-effects (e.g. fatigue and brain fog) were also recorded, supporting a more complete return to normal function.
BHB has been widely studied as an alternative fuel for the brain - shown to support mitochondrial function, activate anti-inflammatory and anti-oxidative pathways and promote neuronal survival.
Klario's advanced combination formula is designed with these broader benefits in mind, while remaining a practical, self-care solution for everyday hypos.
Hypoglycaemia remains a significant burden in insulin-treated diabetes - people with type 1 diabetes experience 100-200 episodes per year. Glucose-only treatments frequently result in suboptimal outcomes:
